July 2026 in “Current Issues in Molecular Biology” This study found that Plerixafor, a CXCR4 antagonist, promotes melanogenesis in melanocytes by increasing MITF and tyrosinase expression and enhancing melanocyte migration, and it effectively restores pigmentation in a mouse depigmentation model without toxicity, highlighting its potential for treating pigmentary disorders.
March 2026 in “Preprints.org” In this study, plerixafor was found to enhance melanogenesis and promote repigmentation by engaging a β-arrestin–β-catenin–MITF signaling axis in melanocytes, and showed effectiveness in restoring depigmentation in a murine model without causing systemic toxicity.
49 citations
,
March 2014 in “Journal of Investigative Dermatology” This study demonstrated that combining AMD3100 with low-dose tacrolimus in a stem cell mobilization approach significantly reduced wound healing time and improved scar and hair follicle regeneration in full-thickness skin wounds.
This study found that combining AMD3100 and low-dose FK506 significantly improved and accelerated the healing of diabetic wounds in rats, suggesting a promising therapeutic approach for wound care in diabetes.
August 2024 in “British Journal of Dermatology” The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.
June 2025 in “British Journal of Dermatology” This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.
112 citations
,
May 2020 in “Nature Communications” This study found that cardiac fibroblasts significantly enhance the maturation of neonatal mouse and human embryonic stem cell-derived cardiomyocytes, suggesting a pivotal role in postnatal heart development and disease.
76 citations
,
July 2019 in “Cellular and Molecular Life Sciences” This article reviews the role of stem cells in tissue development, tumor formation, and organoid generation, and highlights the potential of epigenetic regulation in advancing regenerative medicine and cancer treatment, without presenting new experimental results.
47 citations
,
July 2013 in “Pharmacological Reviews” This review discusses the role of pharmacological sciences in advancing regenerative medicine technologies but reports no new experimental findings; the authors advocate for increased pharmacologist involvement to drive innovations.
35 citations
,
October 2017 in “Trends in Molecular Medicine” This research suggests that targeting the HIF-1α pathway via PHD inhibitors may enable regeneration similar to amphibians in mammals, potentially fast-tracking regenerative therapies from mice to humans.
26 citations
,
April 2019 in “Advances in wound care” This study found that tannic acid accelerated wound healing in rats by modulating inflammatory cytokines, increasing growth factors, and activating the Erk 1/2 pathway.
25 citations
,
September 2013 in “Journal of thoracic oncology” In this animal study, soy isoflavones were found to protect lung tissue from the adverse effects of radiation, such as skin injury, inflammation, and fibrosis, suggesting a potential radioprotective benefit.
17 citations
,
December 2019 in “Stem Cells International” This review examines the recent progress in using bioactive molecules for skin regenerative medicine and reports no new clinical results; the authors suggest this method could become a promising strategy for in situ skin regeneration.
16 citations
,
January 2020 in “Diabetes” In this study using diabetic rat models, the combination of AMD3100 and low-dose FK506 reduced wound healing time and improved microcirculation in diabetic foot ulcers, indicating a promising new systemic therapy.
5 citations
,
February 2024 in “Frontiers in bioengineering and biotechnology” This research review outlines the challenges of diabetic wounds, such as diabetic foot ulcers, and examines the potential of electrospinning nanofiber scaffolds to improve healing by promoting tissue formation, allowing drug release, and enhancing specific wound healing properties.
2 citations
,
October 2015 in “Human Gene Therapy” The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
January 2023 in “Postępy Dermatologii i Alergologii” This review discusses the clinical applications of adipose tissue-derived stem cells in dermatology and plastic surgery, highlighting their potential benefits but also noting existing limitations and concerns.
April 2016 in “Plastic and reconstructive surgery. Global open” This article from the PRS Global Open and ASPS Education Network does not present any new research findings; it likely serves as an introductory or descriptive overview.
September 2002 in “Oncology Times” This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.
2 citations
,
December 2023 in “Journal of clinical immunology” This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
84 citations
,
August 2023 in “Drugs” This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.
24 citations
,
July 2021 in “Pharmaceutics” This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.
February 2026 in “Indian Journal of Skin Allergy” This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.
May 2026 in “Journal of Human Immunity” In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
December 2025 in “Journal of Human Immunity” In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.
May 2011 in “Value in Health” This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.